GLPwatch
Papers (12034)
Page 174 of 201, ranked by citation count.
- Retraction Note: Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.
- [Liraglutide in the treatment of diabetes type 2].
- Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.
- Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.
- Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
- Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.
- Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.
- [Cardiovascular morbidity and mortality in patients with kidney disease].
- Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.
- Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
- Tirzepatide improves angiogenesis after diabetic hindlimb ischemia through Akt/eNOS and ERK1/2 pathways.
- Design and fabrication of a mesoporous silica scaffold for oral delivery of peptides.
- Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes.
- New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
- [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
- Dulaglutide Effect on Proteins Associated With CKD Progression.
- A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.
- Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations.
- Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.
- Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.
- Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.
- Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.
- Liraglutide in diabetes mellitus: More facts and findings.
- Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.
- Oral semaglutide and cardiovascular outcomes: The overlooked variables.
- Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery?
- What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
- Semaglutide-Associated Sequential Unilateral Transient Osteoporosis of The Hip: A Case Report.
- Can semaglutide influence tumor biomarkers? Insight from a clinical case.
- Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.
- Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide.
- [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].
- Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.
- Design of biomimetic chylomicrons based on 1,3-diolein grafted hyaluronic acid to drive biomacromolecules across the intestinal mucosal barrier.
- Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.
- Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.
- Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology.
- Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.
- Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
- Structure-aware fragment assignment for interpreting tandem mass spectrometry of modified and cyclic peptides.
- Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.
- Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.
- Semaglutide exerts anti-pulmonary fibrosis effects by inhibiting cellular senescence through activation of the Sirt1/HSF1/HSPs pathway.
- Current trends in semaglutide therapy and strategies to improve its bioavailability.
- A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications.
- Chronic semaglutide alters ingestive behavior without impairing taste function in mice.
- GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty.
- Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.
- Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series.
- Dual GIPR and GLP-1R Agonist Tirzepatide Is Associated With Fewer Asthma Exacerbations in Adults With Obesity.
- [Semaglutide is safe and effective for prediabetes and obesity in patients with schizofrenia.]
- Legal Challenges to Compounding Drugs for Weight Loss.
- Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.
- [Effect of semaglutide on serum metabolomics in obese patients with type 2 diabetes mellitus complicated with metabolic-associated fatty liver disease].
- Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
- Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling.
- [Cardiovascular Effects of Antidiabetic Therapies].
- Tirzepatide-associated interstitial kidney injury.
- Developing <sup>68</sup>Ga-Labeled Exendin(9-39) Derivatives for PET Imaging of Insulinomas.
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.